Subscribe
Daily Intelligence for Biotech Investors

The deal tapeserious biotech investors actually read

Top news, M&A, BD&L, IPOs, and VC financings — distilled to a 5-minute read every market morning. No hype. No filler. Just the signal.

Trusted by 2,000+ biotech execs, VCs, BD leads, public market investors - free
Latest Editions
Daily
Jun 1
Monday: Lilly's $1.2B gut feeling
Ivonescimab flexes on OS, daraxonrasib doubles survival in pancreatic cancer, and Lilly licenses a gut hormone before lunch.
May 29
Friday: Pfizer reloads oncology with a $10.5B swing
Pfizer inks a 12-asset oncology pact, SHINE wins Europe for Ilumira, and healthcare finally leads the tape.
May 28
Thursday: Blackstone's $1.3B cheque, no strings attached
$1.3B for Apogee with zero dilution, a hepatitis B functional cure from GSK, and a faster FDA clock for Sanofi.
May 27
Wednesday: Lilly's $3.8B vaccine spree
Lilly buys three vaccine makers for up to $3.8B, EMA's CHMP greenlights four, and Kardigan tests the IPO window.
May 26
Tuesday: conference season takes the mic
Lilly posts early Verve data, ASCO names to watch sharpen, and neuromuscular FDA clocks speed up.
2,000+
Subscribers
5×
Issues per week
16+
Research reports
$106.7B
M&A tracked YTD
Research Hub
Live trackers & research
View all →
Live Trackers
Live Tracker
Biotech M&A Tracker 2026
Every control transaction in 2026 — target, acquirer, deal value, premium-to-unaffected, and investor-grade rationale. 40 deals. $109.4B tracked.
Last updated 1 June 2026
Live Tracker
Biotech BD&L Tracker 2026
Licensing and partnering deals — upfronts, milestones, royalties, territory rights, and a one-line why it matters. 59 deals. Up to US$18.5B largest package.
Last updated 1 June 2026
Live Tracker
Biotech IPO Tracker 2026
Every biotech IPO this year — pricing date, proceeds, valuation at pricing, and aftermarket performance. 12 deals. ~$4.0B tracked.
Last updated 30 May 2026
Live Tracker
Biotech Venture Funding Tracker 2026
VC and crossover rounds — company, stage, lead investors, therapeutic area, and what they are building. 87 deals. US$2.1B largest round.
Last updated 30 May 2026
Research
Report
Most Active Biotech Investors 2026
Ranked league table of the most active biotech and biopharma investors in 2026 by qualifying deal participation.
Reference
Biotech Conference Calendar 2026
Major biotech and biopharma conferences in 2026 across the US, UK, and EU, including investor events, scientific catalysts, and partnering meetings.
Report
Top 10 BioPharma M&A Deals of 2025
Ranked list of the 10 biggest biopharma and biotech acquisitions announced in 2025, with stage, therapeutic area, and investor-grade read-through.
Report
Biotech M&A Q1 2026 Report
16 deals, $44B in value, and what the deal tape signals about where strategic buyers are paying up.
Report
2024 Biopharma M&A: Every $1B+ Deal
The complete list of 2024 biopharma acquisitions worth $1B or more — public and private targets.
Reference
Biotech Funding Terms Glossary
Plain-English definitions of the deal terms that appear in press releases, term sheets, IPOs, and M&A announcements.
About BioBucks

BioBucks is a daily newsletter for biotech and biopharma investors — covering M&A, BD&L deals, IPOs, venture rounds, and catalyst-driven market moves, with the framing that institutional dealmakers actually care about.

Every edition is written to be read in under 5 minutes, with the why it matters front and centre. No press release regurgitation. No noise.

Alongside the daily tape, the Research Hub provides live trackers and standalone reports that serve as reference tools for the community.

Who reads BioBucks
VC / GrowthBiotech venture investors tracking the deal environment
BD&LBusiness development professionals monitoring partnerships
Public MarketsBuyside analysts and portfolio managers
FoundersBiotech CEOs watching comps and M&A premiums